Aberrant STAT3 hyper-activation has been estimated to present in over 70% of human cancer and reported in almost all types of malignancies with a poor clinical outcome [5,12,13], and STAT3 together with its relative signaling pathway has long been recognized as a potential therapeutic target [1,5,7,9,12]. Here, STAT3 is linked to cancer.